US 12,454,539 B2
Controlled-delivery cromakalim prodrugs
Thurein M. Htoo, Waban, MA (US); Barbara M. Wirostko, Park City, UT (US); Michael P. Fautsch, Rochester, MN (US); Ian Garnett, Didcot (GB); and Chiara Massarenti, Oxford (GB)
Assigned to Qlaris Bio, Inc., Dedham, MA (US); and Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Qlaris Bio, Inc., Wellesley, MA (US); and Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Jun. 9, 2022, as Appl. No. 17/836,871.
Application 17/836,871 is a continuation of application No. PCT/US2020/064629, filed on Dec. 11, 2020.
Claims priority of provisional application 62/947,342, filed on Dec. 12, 2019.
Prior Publication US 2022/0324890 A1, Oct. 13, 2022
Int. Cl. C07F 9/6558 (2006.01)
CPC C07F 9/65586 (2013.01) 19 Claims
 
1. A compound of the formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.